Rep. Lloyd Doggett (D-TX) Buys Johnson & Johnson (JNJ) Stock
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Lloyd Doggett (D-TX)
- Status:
- Member — House
- State/District:
- TX-37
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 6, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Johnson & Johnson ($JNJ) | Buy | Jun 9, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document.
Key Points
- Democratic Representative Lloyd Doggett disclosed a purchase of Johnson & Johnson shares valued between $1,001 and $15,000 on June 9, 2026, according to a periodic transaction report filed on July 6, 2026.
- Wall Street research firms updated their price targets for the healthcare giant, with Citigroup, RBC Capital, Guggenheim, Leerink Partners, and Wells Fargo issuing or maintaining ratings.
- Johnson & Johnson shares recently traded around $255.31, up about 8.3% since the lawmaker's trade date when the stock closed at $235.84.
Since the trade, $JNJ is down 0.8% after 1 week, up 9.3% after 1 month and up 8.4% to date (from the $235.84 close on Jun 9, 2026).
Get Johnson & Johnson text alerts
We text you when insiders, Congress, analysts or big funds move on $JNJ.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Representative Lloyd Doggett, a Democrat serving Texas's 37th district in the House, disclosed a purchase of Johnson & Johnson (NYSE: JNJ) stock valued between $1,001 and $15,000. According to a periodic transaction report filed under the STOCK Act on July 6, 2026, the trade took place on June 9, 2026. Congressional disclosure rules require lawmakers to report stock transactions within specific windows, though trade amounts are only revealed in broad financial ranges rather than exact figures.
JNJ
Johnson & Johnson
Lloyd Doggett vs. the S&P 500
Hypothetical returns from Lloyd Doggett's disclosed trades, not real profit or advice. How we model this.
Inside Rep. Doggett's Johnson & Johnson Trade
The transaction involved a purchase of healthcare sector shares within the $1,001 to $15,000 range on June 9, 2026. Johnson & Johnson closed at $235.84 on the day of the trade.
Other Institutional Activity in Johnson & Johnson
Large financial institutions adjusted their positions in the healthcare giant recently. Assenagon Asset Management S.A. grew its holdings by 1,051,362 shares, ending with 2,990,726 shares worth about $791,764,801. Ninety One UK reduced its stake by 285,326 shares, finishing with 6,491,294 shares valued at roughly $1,718,505,190. First Citizens Bank & Trust added 22,136 shares to hold 52,947 shares worth about $14,017,188. Zwj Investment Counsel grew its holdings by 6,670 shares, ending with 231,462 shares valued at roughly $61,277,145. Fort Washington Investment Advisors trimmed its position by 539,918 shares, leaving it with 404,591 shares worth about $107,111,429.
Johnson & Johnson Stock Down 0.1%
Johnson & Johnson shares recently traded around $255.31 as of October 16, 2026, sitting up about 8.3% compared to the event-day close of $235.84 on June 9, 2026. The stock has traded between a 52-week low of $184.66 and a 52-week high of $281.07.
Recent Earnings
Johnson & Johnson posted trailing-twelve-month revenue of $99,334,995,968 alongside trailing-twelve-month earnings per share of $6.59. The healthcare enterprise operates with a net profit margin of 16.2% and a return on equity metric supported by its diversified medical technology and pharmaceutical divisions. The next earnings report is scheduled for January 26, 2027.
Dividend
Johnson & Johnson pays an annual dividend with a yield of 2.12% and a payout ratio of 60.7%.
Insider Buying and Selling at Johnson & Johnson
Company insiders executed several transactions during the summer of 2026. Officer Vanessa Broadhurst sold 23,054 shares on July 20, 2026, at an average price of $251.27 for a total value of $5,792,686. Chief Executive Officer Joaquin Boix Duato sold 48,480 shares on August 5, 2026, for a total value of $12,515,010. Officer Elizabeth Forminard sold 15,918 shares on August 6, 2026, for a total value of $4,090,960. Chief Executive Officer Joaquin Boix Duato later sold 123,291 shares on August 13, 2026, for a total value of $32,199,927.
Analysts Set New Price Targets
Wall Street research firms updated their outlooks on the healthcare company in October 2026. On October 5, Citigroup maintained a buy rating and raised its price target to $303.00 from $298.00. RBC Capital maintained an outperform rating on October 6, lifting its target to $290.00 from $287.00. Guggenheim reiterated a buy rating with a target of $287.00 on October 7. Leerink Partners maintained an outperform rating on October 14, adjusting its target to $272.00 from $276.00. Wells Fargo maintained an overweight rating on October 14, adjusting its target to $275.00 from $282.00. Overall, analysts maintain a consensus buy recommendation with a mean price target of $279.41 across 22 opinions.
About Johnson & Johnson
Headquartered in New Brunswick, New Jersey, Johnson & Johnson operates as a global healthcare enterprise. The company researches, develops, manufactures, and sells a wide variety of medical products and treatments. Its operations span two main divisions: Innovative Medicine and MedTech, which provide advanced pharmaceuticals and surgical technologies to patients and providers worldwide.
Bottom Line
Congressman Doggett's reported trade highlights congressional exposure to major healthcare equities. Observers will track the company's upcoming earnings report on January 26, 2027, alongside future periodic transaction reports filed by members of Congress.
Related Filing Alerts
Source: Lloyd Doggett's STOCK Act disclosure on $JNJ (Jun 9, 2026). Written by software, not financial advice. How we make alerts